Components of the insulin resistance syndrome are associated with progression of atherosclerosis in non-grafted arteries 5 years after coronary artery bypass surgery

European Heart Journal

Volumn 19, Issue 5, 1998, Pages 711-719

  Korpilahti, Kari ^a,d   Syvanne M ^b   Engblom, E ^a   Hamalainen H ^c   Puukka, P ^c   Ronnemaa T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c SOCIAL INSURANCE INSTITUTION   (Finland)

^d VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

Atherosclerosis; Coronary bypass surgery; Insulin resistance; Triglycerides

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CLOFIBRATE; DIPYRIDAMOLE; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN; MEVINOLIN; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RISK FACTOR; TIME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CHOLESTEROL; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; SURVIVAL RATE; TRIGLYCERIDES;

EID: 18544398971     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0869     Document Type: Article

References (45)

1. [1] Frick MH, Valle M, Harjola P-T. Progression of coronary artery disease in randomized medical and surgical patients over a 5-year angiographic follow-up. Am J Cardiol 1983; 52: 681-5.
2. [2] Bourassa MG, Lespérance J, Corbara F, Saltiel J, Campeau L. Progression of obstructive coronary artery disease 5 to 7 years after aortocoronary bypass surgery. Circulation 1978; 58 (Suppl I): I-100-I-106.
3. [3] Alderman EL, Corley SD, Fisher LD et al., and the CASS participating investigators and staff. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993; 22: 1141-54.
4. [4] Kane JP, Malloy MJ, Ports TA et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-12.
5. [5] Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipolniacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264: 3013-17.
6. [6] Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
7. [7] Buchwald H, Varco RL, Matts JP et al., and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55.
8. [8] Watts GF, Lewis B, Brunt JNH et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-9.
9. [9] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
10. [10] Sacks FM, Pfeffer MA, Moye LA et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
11. [11] Frick MH,Harjola P-T, Valle M. Persistent improvement after coronary bypass surgery: ergometric and angiographic correlations at 5 years. Circulation 1983; 67: 491-6.
12. [12] Moise A, Bourassa MG, Théroux P et al. Prognostic significance of progression of coronary artery disease. Am J Cardiol 1985; 55: 941-6.
13. [13] Reaven GM, Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
14. [14] Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-22.
15. [15] Després J-P, Lamarche B, Mauriège P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7.
16. [16] Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 1990; 10: 167-75.
17. [17] Engblom E, Rönnemaa T, Hämäläinen H, Kallio V, Vänttinen E, Knuts L-R. Coronary heart disease risk factors before and after bypass surgery: results of a controlled trial on multifactorial rehabilitation. Eur Heart J 1992; 13: 232-7.
18. [18] Engblom E, Korpilahti K, Hämäläinen H, Puukka P, Rönnemaa T. Effects of five years of cardiac rehabilitation after coronary artery bypass grafting on coronary risk factors. Am J Cardiol 1996; 78: 1428-31.
19. [19] Campeau L. Grading of angina pectoris. Letter. Circulation 1976; 54: 522-3.
20. [20] Reiber JHC, van der Zwet PMJ, von Land CD et al. Quantitative coronary arteriography: equipment and technical requirements. In: Reiber JHC, Serruys PW, eds. Advances in quantitative coronary arteriography. Dordrecht: Kluwer Academic Publishers, 1993: 75-111.
21. [21] Syvänne M, Nieminen MS, Frick MH. Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study. Int J Vascular Imaging 1994; 10: 243-52.
22. [22] Blankenhorn DH, Selzer RH, Mack WJ et al. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect. Circulation 1992; 86: 1701-9.
23. [23] Reiber JHC, Serruys PW, Kooijman CJ et al. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 1985; 71: 280-8.
24. [24] Siegel J, Schlumberger H, Klose S, Ziegenhorn J, Wahlefeld AW. Improved reagent for the enzymatic determination of serum cholesterol. J Clin Chem Clin Biochem 1981; 19: 838-9.
25. [25] Wahlefeld AW. Triglycerides - determination after enzymatic hydrolysis. In: Bergmeyer HV, ed. Methods of enzymatic analysis, 2nd edn. New York: Verlag Chemie/Academic Press, 1974: 1831-5.
26. [26] Kostner G. Enzymatic determination of cholesterol in high-density lipoprotein fractions prepared by polyanion precipitation. Clin Chem 1976; 22: 695.
27. [27] Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
28. [28] März W, Siekmeier R, Gross E, Gross W. Determination of lipoprotein (a): enzyme immunoassay and immunoradiometric assay compared. Clin Chem Acta 1993; 214: 153-63.
29. [29] Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric determination of apolipoproteins A-1 and B in serum. Scand J Clin Lab Invest 1987; 47: 739-44.
30. [30] Lehtimäki T, Moilanen T, Viikari J et al. Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res 1990; 31: 487-95.
31. [31] Marshall MD, Kales SN, Christiani DC, Goldman RH. Are reference intervals for carboxyhemoglobin appropriate? A survey of Boston area laboratories. Clin Chem 1995; 41: 1434-8.
32. [32] Hodis HN, Mack WJ, Azen SP et al. Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/ moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90: 42-9.
33. [33] Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post-infarction patients. Lancet 1996; 347: 849-53.
34. [34] Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb Vasc Biol 1996; 16: 697-704.
35. [35] Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-8.
36. [36] Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 1992; 152: 28-34.
37. [37] Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Vasc Biol 1996; 16: 1333-9.
38. [38] Juhan-Vague I, Alessi MC, Value P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-62.
39. [39] Castelli WP, Garrison RJ, Wilson PWF, Abbot RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256: 2835-8.
40. [40] Jacobs Jr DR, Mebane IL, Bangdiwala SI, Crique MH, Tyroler HA, for the Lipid Research Clinics Program. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the lipid research clinics prevalence study. Am J Epidemiol 1990; 131: 32-47.
41. [41] Bressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia 1996; 39: 1345-50.
42. [42] Yarnell JWG, Sweetnam PM, Marks V, Teale JD, Bolton CH. Insulin in ischaemic heart disease: are associations explained by triglyceride concentrations? The Caerphilly prospective study. Br Heart J 1994; 71: 293-6.
43. [43] Fontbonne A, Charles MA, Thibult N et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991; 34: 356-61.
44. [44] Howard G, O'Leary DH, Zaccaro D et al., for the IRAS Investigators. Insulin sensitivity and atherosclerosis. Circulation 1996; 93: 1809-17.
45. [45] Reaven GM, Chen Y-DI. Insulin resistance, its consequences, and coronary heart disease. Must we choose one culprit? Circulation 1996; 93: 1780-3.